Skip Navigation


Cardiovascular Research Advance Access first published online on August 30, 2009
This version [Corrected Proof] published online on September 19, 2009

Cardiovascular Research, doi:10.1093/cvr/cvp300
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow All Versions of this Article:
cvp300v2    most recent
cvp300v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kelly, J. A.
Right arrow Articles by Morganelli, P. M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kelly, J. A.
Right arrow Articles by Morganelli, P. M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org.

Inhibition of arterial lesion progression in CD16-deficient mice: evidence for altered immunity and the role of IL-10

John A. Kelly1,2, Mary E. Griffin1,2, Roy A. Fava1,2, Sheryl G. Wood1,2, Katherine A. Bessette1,2, Elizabeth R. Miller3, Sally A. Huber4, Christoph J. Binder3,5, Joseph L. Witztum3 and Peter M. Morganelli1,2,*

1 Veterans Affairs Medical Center, Code 151, VAM&ROC, 215 N. Main Street, White River Junction, VT 05009, USA
2 Department of Microbiology and Immunology, Dartmouth Medical School, Lebanon, NH, USA
3 Division of Endocrinology and Metabolism, University of California-San Diego, San Diego, CA, USA
4 Department of Pathology, University of Vermont, Burlington, VT, USA
5 Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna, Vienna, Austria

* Corresponding author. Tel: +1 802 295 9363, ext. 5895, Fax: +1 802 296 6308, Email: peter.morganelli{at}dartmouth.edu

Aims: Given the importance of IgG Fc receptors in immune regulation, we hypothesized that Fcg receptor type III (FcgRIII, CD16) plays an important role in atherogenesis. We therefore analysed the formation of arterial lesions in LDL receptor-deficient (LDLR–/–) and FcgRIII–/–xLDLR–/– double knockout mice at three different points up to 24 weeks of exposure to a high-fat diet.

Methods and results: Analysis of Oil Red-O-stained sections revealed no difference in lesion formation between strains after 6 weeks of a high-fat diet, and a modest decrease after 14 weeks in double knockouts relative to LDLR–/– controls. After 24 weeks, lesion formation was decreased in the aortic root (30%) and innominate artery (50%) in FcgRIII double knockouts relative to LDLR–/– controls. Analysis of peripheral CD4+ T-cells by intracellular flow cytometry from double knockouts after 24 weeks of a high-fat diet revealed statistically significant increases in the percentages of cells producing interferon-{gamma}, interleukin (IL)-10, and IL-4 relative to controls, differences that were also observed by analyses of whole aortas for cytokine mRNA levels. As determined by flow cytometry, FcgRIII deficiency resulted in an expansion of CD4+ cells and an increase in the CD4 to CD8 ratio. Analysis of plasma anti-oxidized LDL (OxLDL) antibodies by chemiluminescent assay revealed that IgG1 and IgG2c titers to OxLDL were increased in FcgRIII –/–xLDLR–/– double knockouts relative to LDLR–/– controls, while total IgG levels were similar.

Conclusion: These results reveal altered immunity in FcgRIII–/–xLDLR–/– mice and a reduction in lesion formation associated with increased production of IL-10 by an expansion of CD4+ T-cells. The reduction in lesion formation was manifest well after evidence of an immune response to OxLDL, suggesting that FcgRIII contributes to lesion progression in murine atherosclerosis.

KEYWORDS Fc receptors; CD16; Murine atherosclerosis; T-cells; Oxidized LDL; Lesions; IL-10; Interferon; Lymphoid follicle


Time for primary review: 36 days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.